000908 Hunan Jingfeng Pharmaceutical
- 3.97
- +0.19+5.03%
Hunan Jingfeng Pharmaceutical News
ST Jingfeng (000908.SZ): It has been confirmed that the consortium led by Shiyao Holdings will be the selected restructuring investor.
*ST Jingfeng (000908.SZ) announced that as of August 15, 2024, there were a total of 4 investors...
*ST Jingfeng (000908.SZ): Shareholder Ye Xiangwu's shareholding period is more than half over, with a total shareholding of 1.0448 million shares.
On August 12th, *ST Jingfeng (000908.SZ) announced that the company recently received a notice from shareholder Mr. Ye Xiangwu regarding the shareholding plan of Hunan Jingfeng Pharmaceutical, which has passed the halfway point of its implementation. As of the date of the announcement, Mr. Ye Xiangwu has accumulated 1.0448 million shares of the company's stock through centralized bidding trading on the Shenzhen Stock Exchange system, accounting for 0.12% of the total share capital of the company. The total amount of shareholding reached 2.0029 million yuan (excluding transaction fees), which has reached the lower limit of this shareholding plan.
August 9th A-share lightning rod | Liuzhou Chemical Industry: China Construction Bank Guangxi Branch and China Construction Bank Financial Leasing intend to reduce their total shareholding by no more than 3%; *Guizhou Changzheng Tiancheng Holding: The sto
Beijing Jingxi Culture & Tourism shareholder Qingdao Haifa plans to reduce its shareholding by no more than 3%; Liuzhou Chemical Industry shareholder China Construction Bank Guangxi Branch and Jianxin Golden Lease plan to reduce their shareholding by no more than 3%; The stocks of Guizhou Changzheng Tiancheng Holding, ST, will be delisted and removed from the market on August 15; ST Dong Shi claimed that the China Securities Regulatory Commission has decided to file a case against the actual controller Xu Xiong; ST Jingfeng stated that the recruitment of investors for restructuring has been postponed.
ST Jingfeng (000908.SZ): Recruitment of restructuring investors postponed.
On August 8, Gelonhui reported that special treat Hunan Jingfeng Pharmaceutical (stock code: 000908.SZ) announced that in order to speed up the company's pre-restructuring work, the interim administrator released a notice to recruit potential investors on the national enterprise bankruptcy restructuring case information network on August 1, 2024. On August 2, 2024, the company released a notice on the designated information disclosure media to publicly recruit restructuring investors, and openly recruited and selected pre-restructuring investors from the society. As of August 8, 2024, some potential investors indicated that the time to prepare materials was tight and internal approval had not yet been completed.
* ST Jingfeng (000908.SZ): There may be a risk of a sharp drop in stock price after a significant increase.
*ST Jingfeng (000908.SZ) announced that the company's stocks will be suspended from trading on August 5, 6, and 7, 2024...
ST Jingfeng (000908.SZ): Stocks trade with serious abnormal fluctuations, without disclosing any significant information.
On July 17th, Gelunhui reported that the stock (*ST Jingfeng, stock code: 000908) of Jingfeng has deviated from the closing price for the past three consecutive trading days between July 15th and July 17th of 2024, with a cumulative increase of 17.01%. According to the relevant provisions of the Shenzhen Stock Exchange Trading Rules, it belongs to abnormal fluctuations in stock trading; at the same time, the company's stock has appeared abnormal fluctuations in the same direction in 4 out of the last ten consecutive trading days, which constitutes serious abnormal fluctuations in stock trading. The board of directors confirmed that the company currently has no basis for trading.
Hunan Jingfeng Pharmaceutical: 2024 Interim Performance Forecast
*Special treat Jingfeng (000908.SZ): Expected half-year loss of 15 to 25 million yuan.
On July 9, Gelon Hui reports that ST Jingfeng (000908.SZ) predicts a loss of 15-25 million yuan in the first half of the year, with non-net losses of 18-27 million yuan and operating income of 180-220 million yuan. During the reporting period, due to factors such as insufficient outsourcing production volume of major subsidiary Shanghai Jingfeng Pharmaceutical Co., Ltd., the net profit of the company was negative. During the reporting period, the exclusion of major subsidiary Dalian Deze Pharmaceutical Co., Ltd. from the company's consolidated financial statements had an impact on various key financial indicators.
July 8 A-share lightning rod | Naxin Micro: multiple shareholders plan to reduce their holdings by no more than 6% of shares;* Special Treat Jingfeng: the stock is at risk of being delisted.
Several shareholders of NAXIN Micro plan to reduce their shareholding by no more than 6%. Kaishan Group has about 0.136 billion restricted stocks to be lifted on July 8, accounting for 13.65% of the total shares. Special Treat Jingfeng stock faces the risk of being delisted. Jiangsu Zhongli Group received an administrative penalty decision from the China Securities Regulatory Commission.
Risk Warning for ST Jingfeng (000908.SZ): There is a risk of the company's stocks being delisted.
On July 5th, Gelunhui announced the second risk warning about the possible delisting of * ST Jingfeng (000908.SZ). On July 5, 2024, the closing price of Hunan Jingfeng Pharmaceutical Co., Ltd.'s stock was below 1 yuan for ten consecutive trading days. According to Article 9.2.1 (4) of the Shenzhen Stock Exchange Listing Rules, if the company's stock has a closing price below 1 yuan for twenty consecutive trading days, there is a risk of delisting. According to Article 9.2.4 of the Shenzhen Stock Exchange Listing Rules, the listed company must
ST Jingfeng (000908.SZ): The controlling shareholder plans to increase the shareholding of the company by 2-4 million yuan.
On June 24th, Gelunhui reported that *ST Jingfeng (000908.SZ) announced that the company's controlling shareholder plans to increase its shareholding in the company between June 25th, 2024 and September 24th, 2024 through the Shenzhen Stock Exchange's centralized bidding trading system using its own funds, with a total increase of no less than 2 million yuan (including the principal) and no more than 4 million yuan (including the principal), based on the recognition of the company's long-term investment value and future development prospects.
Little Excitement Around Hunan Jingfeng Pharmaceutical Co.,Ltd.'s (SZSE:000908) Revenues As Shares Take 27% Pounding
Jingfeng Pharmaceutical (000908.SZ) announced first-quarter results, net profit of 3.553 million yuan, an increase of 174.14%
Jingfeng Pharmaceutical (000908.SZ) released its report for the first quarter of 2024. The company's revenue was 1.01...
Hunan Jingfeng Pharmaceutical Co.,Ltd. (SZSE:000908) Looks Inexpensive After Falling 38% But Perhaps Not Attractive Enough
Jingfeng Pharmaceutical (000908.SZ): The company's stock may be subject to a delisting risk warning
Zhitong Finance App News, Jingfeng Pharmaceutical (000908.SZ) issued an announcement. According to preliminary estimates by the company's finance department, the company's net assets are expected to be negative at the end of 2023. If the company's net assets at the end of the 2023 audited period are negative, according to the relevant provisions of the “Shenzhen Stock Exchange Stock Listing Rules”, the company's stock transactions will be subject to a delisting risk warning after disclosing the 2023 annual report.
Jingfeng Pharmaceutical (000069.SZ): The company's stock may be subject to a delisting risk warning
Jingfeng Pharmaceutical (000069.SZ) issued an announcement. According to preliminary estimates by the company's finance department, the company expects 2023...
Even After Rising 19% This Past Week, Hunan Jingfeng PharmaceuticalLtd (SZSE:000908) Shareholders Are Still Down 49% Over the Past Five Years
Lacklustre Performance Is Driving Hunan Jingfeng Pharmaceutical Co.,Ltd.'s (SZSE:000908) 29% Price Drop
Jingfeng Pharmaceutical (000908.SZ): Expected net loss of 190 million yuan to 230 million yuan in 2023
Gelonghui, January 29丨Jingfeng Pharmaceutical (000908.SZ) announced that it expects a net loss of 190 million yuan to 230 million yuan in 2023, deducting non-net loss of 190 million yuan to 240 million yuan, and operating income of 650 million yuan to 80 million yuan. The main reasons for the changes in the company's performance in 2023:1. The company's important product, Shenxiao Glucose Injection, withdrew from the medical insurance catalogue, and product sales dropped sharply compared to the same period last year; 2. Sales volume of the company's important product, sodium hyaluronate injection, fell short of expectations; 3. Dalian Deze Pharmaceutical Co., Ltd., an important subsidiary of the company, due to the operating period
Jingfeng Pharmaceutical (000908.SZ): The holding subsidiary has been applied for liquidation
Gelonghui November 24 | Jingfeng Pharmaceutical (000908.SZ) announced that Dalian Deze Pharmaceutical Co., Ltd., a holding subsidiary of Shanghai Jingfeng Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Shanghai Jingfeng Pharmaceutical Co., Ltd., recently received a “Civil Ruling” from the Dalian Intermediate People's Court, ruling to revoke the civil ruling of the People's Court of Jinzhou District of Dalian City. The case was handled by the People's Court of Jinzhou District of Dalian City. Shanghai Jingfeng Pharmaceutical Co., Ltd. has objections to the above ruling of the Dalian Intermediate People's Court in Liaoning Province and has appointed lawyers to defend its rights in accordance with the law. There is uncertainty about whether Dalian Deze Pharmaceutical Co., Ltd. will eventually be forcibly liquidated. The company will pay close attention to the matter after
Analysis
Price Target
No Data
